Year-end Report 2020

2020-10-01 – 2020-12-31 (fourth quarter)

  • Consolidated net sales amounted to TSEK 0 (0).
  • The Group’s profit before tax amounted to TSEK -9 786 (-11 203).
  • The Group’s earnings per share amounted to SEK -0,35 (-0,68).
  • The average number of shares for the period was 24 406 295.

2020-01-01 – 2020-12-31 (twelve months)

  • Consolidated net sales amounted to TSEK 0 (0).
  • The Group’s profit before tax amounted to TSEK -31 304 (-27 637).
  • The Group’s earnings per share amounted to SEK -1,23 (-1,63).
  • The equity ratio was 73% (47%).
  • The average number of shares for the period was 21 549 984.

“SynAct Pharma AB” means the parent company SynAct Pharma AB with corporate identity number 559058–4826. “The Company” or “SynAct” means the Group, i.e. SynAct Pharma AB and its wholly owned subsidiary SynAct Pharma ApS.

Definitions

  • Earnings per share: Profit for the period divided by the average number of outstanding shares in the period.
  • Equity ratio: Equity divided by total capital.

Significant events in Q4 2020

  • On October 12, SynAct successfully completed the second cohort (100 mg dose level) in Part 1 of the Phase II clinical study with AP1189 for rheumatoid arthritis.
  • On November 6, Dr. Uli Hacksellwas elected as the new boardmember.
  • On November 9, SynAct Pharma announced positive interim data from the Phase 2 study with AP1189 in Rheumatoid Arthritis.

Significant events in Q1-Q3 2020

  • On February 7, SynAct updated its development plans.
  • On March 31, SynAct announced that the company is investigating the possibility of testing AP1189 as an adjunct therapy in hospitalized patients with COVID-19.
  • On March 31, SynAct submitted a clinical trial application for AP1189 in nephronic syndrome.
  • On April 3, SynAct applied for a patent for AP1189 in COVID-19.
  • On May 5, synact updated phase II study with AP1189 in rheumatoid arthritis.
  • On May 25, SynAct filed an international patent application under the Patent Coordination Treaty (PCT) to cover combination therapy with drug candidate AP1189 and Methotrexate (MTX) for the treatment of rheumatoid arthritis and other diseases in arthritis.
  • On 2 June, the Phase II application was approved by the Danish Authority.
  • On June 29, SynAct initiated a phase II clinical study with drug candidate AP1189 in idiopathic membranous nephropathy patients with nephrotic syndrome.
  • On July 15, SynAct announced progress in the second dose level (100 mg) in Part 1 of the Phase II clinical study with AP1189 in patients with rheumatoid arthritis and high disease activity in clinics in Denmark and Sweden.
  • On July 27, SynAct received approximately MSEK 32,4 in the option exercise of series TO 2 warrants.
  • On August 28, SynAct initiated the scientific and clinical collaboration RESOVIR to explore AP1189 in viral infections. The first step in the collaboration will be to conduct an exploratory clinical study on COVID-19 infected patients aimed at investigating repeated dosing of the company’s clinical drug candidate AP1189.
  • On September 3, the company announced that the recruitment for Part 1 of the Phase II clinical study with AP1189 in rheumatoid arthritis is complete.
  • On September 23, SynAct initiated a Phase II study with AP1189 for the treatment of ARDS in COVID-19 patients in clinical departments in Brazil in a collaboration between SynAct, Queen MaryUniversity, London, United Kingdom, and Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Significant events after the end of the period

  • On January 11, 2021, board member and CSO Thomas Jonassen and CEO Jeppe Øvlesen undertook a corporate restructuring in which the respective holdings of shares in SynAct have been transferred to the newly formed company BioInvest ApS.
  • January 26, 2021, SynAct Pharma named Thomas Boesen as Chief Operating Officer
  • February 4, 2021 SynAct announced that it is preparing to move to Nasdaq Stockholm
  • On February 5, 2021, SynAct announced a directed share issue of MSEK 80.
  • February 11, 2021, SynAct Pharma appointed James Knight Chief Business Officer

For more information, please contact:

Jeppe Øvlesen                                                                             Thomas Jonassen
CEO, SynAct Pharma AB                                                           CSO, SynAct Pharma AB
Phone: +45 28 44 75 67                                                            Phone: +45 40 15 66 69
Email: joo@synactpharma.com                                                  Email: tj@synactpharma.com